Starvation in the Treatment of Diabetic Ketoacidosis
Launched by TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER · Dec 15, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males and females with the diagnosis of diabetic ketoacidosis (defined as blood glucose greater than 250 mg/dL, arterial pH less than 7.3, serum bicarbonate less than 15 mEq/L, and the presence of ketonemia or ketonuria)
- • Age between 18-89
- • Admission to the Medical Intensive Care Unit
- • Able to provide informed consent
- Exclusion Criteria:
- • Pregnant and breast-feeding women
- • Institutionalized patients or prisoners
- • Patients unable to eat by mouth, including intubation, presence of any tube used for enteral feeding (nasogastric tube, orogastric tube, PEG tube, etc.), medical conditions requiring parenteral feeding, and a history of a medical condition that prevented oral intake prior to admission, including achalasia, esophageal cancer, stroke with residual deficits preventing oral intake, amyotrophic lateral sclerosis, or head and neck trauma.
About Texas Tech University Health Sciences Center
Texas Tech University Health Sciences Center (TTUHSC) is a prominent academic institution dedicated to improving health outcomes through innovative research, education, and clinical practice. As a leading sponsor of clinical trials, TTUHSC leverages its interdisciplinary expertise to advance medical knowledge and patient care. The institution is committed to conducting rigorous, ethically sound research that adheres to the highest standards of scientific integrity. With a focus on diverse health issues, TTUHSC fosters collaboration among healthcare professionals, researchers, and community stakeholders to translate research findings into effective treatments and interventions for the benefit of the populations it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lubbock, Texas, United States
Patients applied
Trial Officials
Kenneth Kenneth, MD
Principal Investigator
Texas Tech University Health Science Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported